Overview
What is Tenofovir Alafenamide (TAF)?
Tenofovir alafenamide (TAF) is a newer prodrug of tenofovir designed to deliver the active drug more efficiently inside cells. Compared to the older TDF (tenofovir disoproxil fumarate), TAF uses a much lower dose (10–25 mg vs 300 mg), resulting in far lower plasma tenofovir levels and significantly less kidney and bone side effects.
Mechanism
How Does It Work?
1
Efficient cell uptake
TAF is a phosphonamidate prodrug that preferentially enters lymphocytes and hepatocytes, where it is converted to tenofovir diphosphate (TFV-DP).
2
Intracellular activation
Because activation occurs inside the target cell rather than in plasma, much lower doses achieve equivalent or higher intracellular TFV-DP concentrations than TDF, sparing kidneys and bones from high plasma exposure.
3
Chain termination
TFV-DP competes with dATP for incorporation into viral DNA, causing premature chain termination of HIV reverse transcription or HBV polymerase activity.
Dosage
How to Use
Timing
Once daily, at the same time each day
How to Take
Swallow whole with water. Can be taken with or without food.
With Food
Can be taken with or without food
Alcohol
Avoid excessive alcohol
Missed Dose
Take as soon as remembered. If close to next dose, skip the missed dose. Never double dose.
Safety
Side Effects & Precautions
Common Side Effects
- Nausea
- Headache
- Fatigue
- Abdominal pain
- Diarrhoea
Serious Side Effects — seek help immediately
- Lactic acidosis
- Severe hepatomegaly with steatosis
- Severe acute HBV exacerbation on discontinuation (HBV-infected patients)
- Renal impairment (less common than TDF)
Who Should Not Take This
- Concurrent use with TDF-containing products
- Severe hepatic impairment
Value
Generic vs Brand
Generic (OnlineMeds)
Vemlidy
Price per unit
$45.00
$800–$1400/month
Active ingredient
Identical
Identical
Storage
Storage & Handling
Temperature
Below 30°C in original bottle
Light
Keep in original bottle
Humidity
Do not remove desiccant; protect from moisture
Children
Keep out of reach of children.
Why OnlineMeds
Why Buy From Us
Manufacturer Direct
Sourced directly from WHO-GMP certified manufacturers.
Quality Verified
Every batch tested for purity and bioequivalence.
Global Delivery
Discreet shipping to UK, US, AU, EU and beyond.
Licensed Pharmacy
Regulated and compliant with international pharmacy standards.
FAQ
Frequently Asked Questions
What is the difference between TAF and TDF in Hepbest 25 mg Tablets?
TAF (tenofovir alafenamide) is a newer prodrug that activates inside the target cell rather than in the bloodstream. This means a much lower dose (25 mg vs 300 mg for TDF) delivers equivalent or greater activity at the site of infection, while causing significantly less exposure to the kidneys and bones.
Is Tenofovir Alafenamide (TAF) safer for kidneys than older tenofovir?
Yes — clinical studies show TAF causes significantly less reduction in kidney function and less loss of bone density compared to TDF, because plasma tenofovir levels are much lower. It is preferred for patients with pre-existing kidney disease or osteoporosis.
Can Hepbest 25 mg Tablets treat Hepatitis B as well as HIV?
Yes. TAF (as Vemlidy) is specifically approved for chronic Hepatitis B at 25 mg once daily. It is also present in HIV combination tablets (e.g. Biktarvy, Descovy) where it treats both HIV and any co-existing HBV infection.
What happens if I stop taking Hepbest 25 mg Tablets when I have Hepatitis B?
Stopping TAF abruptly in HBV-infected patients can cause a severe flare of Hepatitis B that may result in serious liver damage or liver failure. Always consult your doctor before stopping, and liver function will need to be monitored closely for several months after discontinuation.
⚠ BLACK BOX WARNING
Severe acute exacerbation of Hepatitis B has been reported in HBV-infected patients who discontinued TAF. Hepatic function should be monitored closely for at least several months in these patients.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with nucleoside analogues.
Drug Interactions
| Drug / Substance | Effect | Action |
|---|
| Rifampicin |
Reduces TAF levels — may compromise efficacy |
Avoid; consult specialist for alternative |
| Rifabutin |
Moderately reduces TAF exposure |
Increase TAF dose or avoid |
| P-gp inducers (carbamazepine, St John's Wort) |
Reduce TAF plasma levels |
Avoid concurrent use |
| TDF-containing products |
Duplication of tenofovir — increased toxicity |
Do not use concurrently |
Approved Indications
-
HIV-1 infection (in combination regimens) FDA / EMA
-
Chronic Hepatitis B in adults and children ≥ 2 years (Vemlidy) FDA / EMA
References
-
Gilead Sciences. FDA Prescribing Information: Vemlidy (tenofovir alafenamide). ↗
-
WHO. WHO Consolidated Guidelines on HIV Treatment, 2021. ↗
Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Used as prescribed by a licensed medical professional.
